SMZ1 Stock Overview
An investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Sino Biopharmaceutical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.40 |
| 52 Week High | HK$0.48 |
| 52 Week Low | HK$0.29 |
| Beta | 0.69 |
| 11 Month Change | -2.68% |
| 3 Month Change | 11.98% |
| 1 Year Change | -9.09% |
| 33 Year Change | -38.32% |
| 5 Year Change | -48.28% |
| Change since IPO | 3,950.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| SMZ1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | 0.8% |
| 1Y | -9.1% | -18.4% | 9.1% |
Return vs Industry: SMZ1 exceeded the German Pharmaceuticals industry which returned -18.4% over the past year.
Return vs Market: SMZ1 underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| SMZ1 volatility | |
|---|---|
| SMZ1 Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SMZ1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: SMZ1's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 24,437 | Eric S. Y. Tse | www.sinobiopharm.com |
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.
Sino Biopharmaceutical Limited Fundamentals Summary
| SMZ1 fundamental statistics | |
|---|---|
| Market cap | €7.26b |
| Earnings (TTM) | €282.70m |
| Revenue (TTM) | €3.67b |
25.7x
P/E Ratio2.0x
P/S RatioIs SMZ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SMZ1 income statement (TTM) | |
|---|---|
| Revenue | CN¥27.79b |
| Cost of Revenue | CN¥5.23b |
| Gross Profit | CN¥22.56b |
| Other Expenses | CN¥20.41b |
| Earnings | CN¥2.14b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 81.16% |
| Net Profit Margin | 7.71% |
| Debt/Equity Ratio | 22.6% |
How did SMZ1 perform over the long term?
See historical performance and comparison